{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:20:27Z","timestamp":1783527627089,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e9 d'Angers"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>VEXAS syndrome is characterized by high glucocorticoid (GC) requirements and frequent relapses during tapering, yet dose\u2013response relationships remain poorly defined. We conducted a pilot study to assess the feasibility of granular longitudinal treatment-line reconstruction and to explore GC dose\u2013response patterns associated with disease activity and flare risk. In this retrospective single-center study, we reconstructed detailed treatment trajectories of patients with VEXAS syndrome. Disease courses were segmented into treatment-line periods defined by any therapeutic modification, including GC dose changes. For each period, GC dose, concomitant therapies, and clinical activity were recorded. Associations between GC dose and disease activity were analyzed using multivariable models adjusting for concomitant treatments. Twelve patients were included, representing 315 treatment-line periods over a mean follow-up of 45\u00a0months. Mean annual GC exposure was 3.27\u2009\u00b1\u20092.26\u00a0g per patient. Higher GC dose (continuous variable) was independently associated with lower odds of clinical activity (aOR 0.91 per mg increase [95% CI 0.88\u20130.94], p\u2009&lt;\u20090.001). Exploratory threshold analyses suggested increased flare risk below approximately 15\u00a0mg\/day (or 0.2\u00a0mg\/kg\/day), with a lower-risk plateau above 20\u00a0mg\/day. The increased flare risk below 15\u00a0mg\/day remained significant after adjustment for concomitant therapies (HR 0.24 [95% CI 0.11\u20130.54], p\u2009=\u20090.001). Organ-specific analyses suggested heterogeneous glucocorticoid sensitivity, with higher doses appearing required for lung involvement and lower doses appearing sufficient for fever, skin, and joint manifestations. This pilot study demonstrates the feasibility of detailed treatment-line reconstruction in VEXAS syndrome and identifies GC dose\u2013response trends. These preliminary findings provide planning parameters for a future adequately powered study aimed at validating dose thresholds and refining tapering strategies in VEXAS.<\/jats:p>","DOI":"10.1007\/s00296-026-06130-3","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:27:10Z","timestamp":1779200830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring glucocorticoid dose\u2013response patterns in VEXAS syndrome: a pilot retrospective study"],"prefix":"10.1007","volume":"46","author":[{"given":"Nicolas","family":"Giachetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-3272","authenticated-orcid":false,"given":"J\u00e9rome","family":"Hadjadj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Gaudr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2538-0076","authenticated-orcid":false,"given":"Christian","family":"Lavigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7184-752X","authenticated-orcid":false,"given":"Valentin","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"6130_CR1","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA et al (2020) Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 383:2628\u20132638. https:\/\/doi.org\/10.1056\/NEJMoa2026834","journal-title":"N Engl J Med"},{"key":"6130_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.20805","volume":"186","author":"S Georgin-Lavialle","year":"2021","unstructured":"Georgin-Lavialle S, Terrier B, Guedon AF et al (2021) Further characterization of clinical and laboratory features occurring in VEXAS syndrome in a large-scale analysis of multicenter case-series of 116 French patients. Br J Dermatol 186:564\u2013574. https:\/\/doi.org\/10.1111\/bjd.20805","journal-title":"Br J Dermatol"},{"key":"6130_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1001\/jamaoto.2021.4092","volume":"148","author":"S Beaumesnil","year":"2022","unstructured":"Beaumesnil S, Boucher S, Lavigne C et al (2022) Ear, nose, throat, and bronchial involvements in VEXAS syndrome: specifying the spectrum of clinical features. JAMA Otolaryngol Head Neck Surg 148:284\u2013286. https:\/\/doi.org\/10.1001\/jamaoto.2021.4092","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"6130_CR4","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00296-022-05266-2","volume":"43","author":"K Kouranloo","year":"2023","unstructured":"Kouranloo K, Ashley A, Zhao SS, Dey M (2023) Pulmonary manifestations in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome: a systematic review. Rheumatol Int 43:1023\u20131032. https:\/\/doi.org\/10.1007\/s00296-022-05266-2","journal-title":"Rheumatol Int"},{"key":"6130_CR5","doi-asserted-by":"publisher","DOI":"10.7326\/L21-0023","author":"V Lacombe","year":"2021","unstructured":"Lacombe V, Kosmider O, Pr\u00e9vost M et al (2021) Severe joint involvement in VEXAS syndrome: a case report. Ann Intern Med. https:\/\/doi.org\/10.7326\/L21-0023","journal-title":"Ann Intern Med"},{"key":"6130_CR6","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/S2352-3026(23)00375-7","volume":"11","author":"V Lacombe","year":"2024","unstructured":"Lacombe V, Hadjadj J, Georgin-Lavialle S et al (2024) Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond. Lancet Haematol 11:e160\u2013e167. https:\/\/doi.org\/10.1016\/S2352-3026(23)00375-7","journal-title":"Lancet Haematol"},{"key":"6130_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225640","author":"J Hadjadj","year":"2024","unstructured":"Hadjadj J, Nguyen Y, Mouloudj D et al (2024) Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard-2024-225640","journal-title":"Ann Rheum Dis"},{"key":"6130_CR8","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood.2022016642","volume":"140","author":"M Heiblig","year":"2022","unstructured":"Heiblig M, Ferrada MA, Koster MJ et al (2022) Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood 140:927\u2013931. https:\/\/doi.org\/10.1182\/blood.2022016642","journal-title":"Blood"},{"key":"6130_CR9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028133","author":"V Jachiet","year":"2025","unstructured":"Jachiet V, Kosmider O, Beydon M et al (2025) Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from the FRENVEX group. Blood. https:\/\/doi.org\/10.1182\/blood.2024028133","journal-title":"Blood"},{"key":"6130_CR10","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/S2665-9913(25)00034-7","volume":"7","author":"A Al-Hakim","year":"2025","unstructured":"Al-Hakim A, Trikha R, Phyu Htut EE et al (2025) Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study. Lancet Rheumatol 7:e472\u2013e484. https:\/\/doi.org\/10.1016\/S2665-9913(25)00034-7","journal-title":"Lancet Rheumatol"},{"key":"6130_CR11","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00296-023-05513-0","volume":"44","author":"K Kouranloo","year":"2023","unstructured":"Kouranloo K, Dey M, Almutawa J et al (2023) Clinical characteristics, disease trajectories and management of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a systematic review. Rheumatol Int 44:1219\u20131232. https:\/\/doi.org\/10.1007\/s00296-023-05513-0","journal-title":"Rheumatol Int"},{"key":"6130_CR12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ard.2025.05.021","volume":"85","author":"BA Turturice","year":"2025","unstructured":"Turturice BA, Fike A, Patel BA et al (2025) Disease trajectories and glucocorticoid exposure in VEXAS syndrome treated with cytokine-directed therapies. Ann Rheum Dis 85:370\u2013378. https:\/\/doi.org\/10.1016\/j.ard.2025.05.021","journal-title":"Ann Rheum Dis"},{"key":"6130_CR13","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1093\/rheumatology\/keae530","volume":"64","author":"Y Kirino","year":"2025","unstructured":"Kirino Y, Maeda A, Asano T et al (2025) Low remission rates and high incidence of adverse events in a prospective VEXAS syndrome registry. Rheumatol (Oxf) 64:3872\u20133878. https:\/\/doi.org\/10.1093\/rheumatology\/keae530","journal-title":"Rheumatol (Oxf)"},{"key":"6130_CR14","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1016\/j.mayocp.2021.06.006","volume":"96","author":"MJ Koster","year":"2021","unstructured":"Koster MJ, Kourelis T, Reichard KK et al (2021) Clinical heterogeneity of the VEXAS syndrome. Mayo Clin Proc 96:2653\u20132659. https:\/\/doi.org\/10.1016\/j.mayocp.2021.06.006","journal-title":"Mayo Clin Proc"},{"key":"6130_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/art.43287","volume":"78","author":"AM Mekinian","year":"2025","unstructured":"Mekinian AM, Georgin-Lavaille S, Ferrada MA et al (2025) American College of Rheumatology guidance statement for diagnosis and management of VEXAS developed by the International VEXAS working group expert panel. Arthritis Rheumatol 78:509\u2013522. https:\/\/doi.org\/10.1002\/art.43287","journal-title":"Arthritis Rheumatol"},{"key":"6130_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","volume":"15","author":"M Oray","year":"2016","unstructured":"Oray M, Abu Samra K, Ebrahimiadib N et al (2016) Long-term side effects of glucocorticoids. Expert Opin Drug Saf 15:457\u2013465. https:\/\/doi.org\/10.1517\/14740338.2016.1140743","journal-title":"Expert Opin Drug Saf"},{"key":"6130_CR17","doi-asserted-by":"publisher","first-page":"e734","DOI":"10.1016\/S2665-9913(25)00225-5","volume":"7","author":"V Ribier","year":"2025","unstructured":"Ribier V, Hadjadj J, Jachiet V et al (2025) Mapping the infectious burden in VEXAS syndrome: a systematic review and rationale for prevention. Lancet Rheumatol 7:e734\u2013e744. https:\/\/doi.org\/10.1016\/S2665-9913(25)00225-5","journal-title":"Lancet Rheumatol"},{"key":"6130_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/ard-2023-224819","volume":"83","author":"B De Valence","year":"2024","unstructured":"De Valence B, Delaune M, Nguyen Y et al (2024) Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry. Ann Rheum Dis 83:372\u2013381. https:\/\/doi.org\/10.1136\/ard-2023-224819","journal-title":"Ann Rheum Dis"},{"key":"6130_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae405","volume":"11","author":"M Czech","year":"2024","unstructured":"Czech M, Cuellar-Rodriguez J, Patel BA et al (2024) Opportunistic infections, mortality risk, and prevention strategies in patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. Open Forum Infect Dis 11:ofae405. https:\/\/doi.org\/10.1093\/ofid\/ofae405","journal-title":"Open Forum Infect Dis"},{"key":"6130_CR20","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.ard.2025.06.475","volume":"84","author":"LD Weeks","year":"2025","unstructured":"Weeks LD, Hammond D, Savic S et al (2025) POS1124 development of a consensus definition of VEXAS flare for use in clinical research. Ann Rheum Dis 84:1206. https:\/\/doi.org\/10.1016\/j.ard.2025.06.475","journal-title":"Ann Rheum Dis"},{"key":"6130_CR21","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2024.39.e225","volume":"39","author":"IC Benlidayi","year":"2024","unstructured":"Benlidayi IC, Gupta L (2024) CAse-BAsed REview sTandards (CABARET): considerations for authors, reviewers, and editors. J Korean Med Sci 39:e225. https:\/\/doi.org\/10.3346\/jkms.2024.39.e225","journal-title":"J Korean Med Sci"},{"key":"6130_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00296-025-05963-8","volume":"45","author":"G Rana","year":"2025","unstructured":"Rana G, Singh G, Mehta M, Mollaeian A (2025) From diagnostic uncertainty to targeted therapy: a case-based review of VEXAS syndrome. Rheumatol Int 45:217. https:\/\/doi.org\/10.1007\/s00296-025-05963-8","journal-title":"Rheumatol Int"},{"key":"6130_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S et al (2017) Trial of tocilizumab in giant-cell arteritis. N Engl J Med 377:317\u2013328. https:\/\/doi.org\/10.1056\/NEJMoa1613849","journal-title":"N Engl J Med"},{"key":"6130_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, Bekker P (2021) Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384:599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2023386","journal-title":"N Engl J Med"},{"key":"6130_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002255","volume":"8","author":"M-Y Khitri","year":"2022","unstructured":"Khitri M-Y, Guedon AF, Georgin-Lavialle S et al (2022) Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients. RMD Open 8:e002255. https:\/\/doi.org\/10.1136\/rmdopen-2022-002255","journal-title":"RMD Open"},{"key":"6130_CR26","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3899\/jrheum.141347","volume":"42","author":"TA Kermani","year":"2015","unstructured":"Kermani TA, Warrington KJ, Cuthbertson D et al (2015) Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J Rheumatol 42:1213\u20131217. https:\/\/doi.org\/10.3899\/jrheum.141347","journal-title":"J Rheumatol"},{"key":"6130_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/annrheumdis-2019-216303","volume":"79","author":"A Mathian","year":"2020","unstructured":"Mathian A, Pha M, Haroche J et al (2020) Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. Ann Rheum Dis 79:339\u2013346. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216303","journal-title":"Ann Rheum Dis"},{"key":"6130_CR28","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1182\/blood.2022016985","volume":"140","author":"MA Ferrada","year":"2022","unstructured":"Ferrada MA, Savic S, Cardona DO et al (2022) Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood 140:1496\u20131506. https:\/\/doi.org\/10.1182\/blood.2022016985","journal-title":"Blood"},{"key":"6130_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3899\/jrheum.160214","volume":"45","author":"H-L Chen","year":"2018","unstructured":"Chen H-L, Shen L-J, Hsu P-N et al (2018) Cumulative burden of glucocorticoid-related adverse events in patients with systemic lupus erythematosus: findings from a 12-year longitudinal study. J Rheumatol 45:83\u201389. https:\/\/doi.org\/10.3899\/jrheum.160214","journal-title":"J Rheumatol"},{"key":"6130_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000066","author":"SA Sawah","year":"2015","unstructured":"Sawah SA, Zhang X, Zhu B et al (2015) Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus\u2014the Hopkins Lupus Cohort. Lupus Sci Med. https:\/\/doi.org\/10.1136\/lupus-2014-000066","journal-title":"Lupus Sci Med"},{"key":"6130_CR31","doi-asserted-by":"publisher","first-page":"870","DOI":"10.7326\/M20-1594","volume":"173","author":"MD George","year":"2020","unstructured":"George MD, Baker JF, Winthrop K et al (2020) Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis. Ann Intern Med 173:870\u2013878. https:\/\/doi.org\/10.7326\/M20-1594","journal-title":"Ann Intern Med"},{"key":"6130_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019173","volume":"99","author":"D Waki","year":"2020","unstructured":"Waki D, Nishimura K, Tokumasu H et al (2020) Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective observational study. Medicine 99:e19173. https:\/\/doi.org\/10.1097\/MD.0000000000019173","journal-title":"Medicine"},{"key":"6130_CR33","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.semarthrit.2016.11.006","volume":"46","author":"JC Wilson","year":"2017","unstructured":"Wilson JC, Sarsour K, Collinson N et al (2017) Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): a nested case-control analysis. Semin Arthritis Rheum 46:819\u2013827. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.11.006","journal-title":"Semin Arthritis Rheum"},{"key":"6130_CR34","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.semarthrit.2016.10.001","volume":"46","author":"JC Wilson","year":"2017","unstructured":"Wilson JC, Sarsour K, Collinson N et al (2017) Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis. Semin Arthritis Rheum 46:650\u2013656. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.10.001","journal-title":"Semin Arthritis Rheum"},{"key":"6130_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59890-0","volume":"16","author":"H Mizumaki","year":"2025","unstructured":"Mizumaki H, Gao S, Wu Z et al (2025) In depth transcriptomic profiling defines a landscape of dysfunctional immune responses in patients with VEXAS syndrome. Nat Commun 16:4690. https:\/\/doi.org\/10.1038\/s41467-025-59890-0","journal-title":"Nat Commun"},{"key":"6130_CR36","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1182\/blood.2024028216","volume":"146","author":"P Breillat","year":"2025","unstructured":"Breillat P, Carbone F, Lereclus E et al (2025) Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome. Blood 146:1950\u20131963. https:\/\/doi.org\/10.1182\/blood.2024028216","journal-title":"Blood"},{"key":"6130_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44811-4","volume":"15","author":"O Kosmider","year":"2024","unstructured":"Kosmider O, Poss\u00e9m\u00e9 C, Templ\u00e9 M et al (2024) VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation. Nat Commun 15:910. https:\/\/doi.org\/10.1038\/s41467-024-44811-4","journal-title":"Nat Commun"},{"key":"6130_CR38","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/clinids\/11.6.954","volume":"11","author":"AE Stuck","year":"1989","unstructured":"Stuck AE, Minder CE, Frey FJ (1989) Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11:954\u2013963. https:\/\/doi.org\/10.1093\/clinids\/11.6.954","journal-title":"Rev Infect Dis"},{"key":"6130_CR39","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.4049\/jimmunol.1700443","volume":"199","author":"F Kong","year":"2017","unstructured":"Kong F, Liu Z, Jain VG et al (2017) Inhibition of IRAK1 ubiquitination determines glucocorticoid sensitivity for TLR9-induced inflammation in macrophages. J Immunol 199:3654\u20133667. https:\/\/doi.org\/10.4049\/jimmunol.1700443","journal-title":"J Immunol"},{"key":"6130_CR40","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.steroids.2005.02.006","volume":"70","author":"J Zhou","year":"2005","unstructured":"Zhou J, Cidlowski J (2005) The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 70:407\u2013417. https:\/\/doi.org\/10.1016\/j.steroids.2005.02.006","journal-title":"Steroids"},{"key":"6130_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.tips.2018.11.002","volume":"40","author":"RA Panettieri","year":"2019","unstructured":"Panettieri RA, Schaafsma D, Amrani Y et al (2019) Non-genomic effects of glucocorticoids: an updated view. Trends Pharmacol Sci 40:38\u201349. https:\/\/doi.org\/10.1016\/j.tips.2018.11.002","journal-title":"Trends Pharmacol Sci"},{"key":"6130_CR42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.coph.2020.03.003","volume":"53","author":"AP Syed","year":"2020","unstructured":"Syed AP, Greulich F, Ansari SA, Uhlenhaut NH (2020) Anti-inflammatory glucocorticoid action: genomic insights and emerging concepts. Curr Opin Pharmacol 53:35\u201344. https:\/\/doi.org\/10.1016\/j.coph.2020.03.003","journal-title":"Curr Opin Pharmacol"},{"key":"6130_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.imbio.2007.06.004","volume":"213","author":"L P\u00e1link\u00e1s","year":"2008","unstructured":"P\u00e1link\u00e1s L, Talab\u00e9r G, Boldizs\u00e1r F et al (2008) Developmental shift in TcR-mediated rescue of thymocytes from glucocorticoid-induced apoptosis. Immunobiology 213:39\u201350. https:\/\/doi.org\/10.1016\/j.imbio.2007.06.004","journal-title":"Immunobiology"},{"key":"6130_CR44","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41591-025-03623-9","volume":"31","author":"R Molteni","year":"2025","unstructured":"Molteni R, Fiumara M, Campochiaro C et al (2025) Mechanisms of hematopoietic clonal dominance in VEXAS syndrome. Nat Med 31:1911\u20131924. https:\/\/doi.org\/10.1038\/s41591-025-03623-9","journal-title":"Nat Med"},{"key":"6130_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00262-5","volume":"11","author":"V Lacombe","year":"2022","unstructured":"Lacombe V, Beucher A, Urbanski G et al (2022) Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome. Exp Hematol Oncol 11:6. https:\/\/doi.org\/10.1186\/s40164-022-00262-5","journal-title":"Exp Hematol Oncol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06130-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06130-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06130-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:39:01Z","timestamp":1783525141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06130-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["6130"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06130-3","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors NG, JH, NG, CL, and VL declare that they have no conflict of interest. The authors confirm that this manuscript is original, has not been published previously in whole or in part, and is not under consideration for publication elsewhere. Part of this work has been submitted as an abstract to the French National Congress of Internal Medicine (SNFMI).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors used ChatGPT (OpenAI, GPT-5) to improve the English language quality of the manuscript (grammar, vocabulary, and stylistic clarity). The tool was not used for study design, data collection, data analysis, or result interpretation. All AI-assisted outputs were critically reviewed, revised, edited and validated by the authors, who take full responsibility for the final content of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of AI tools"}}],"article-number":"88"}}